Phase 2 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Jun 2013 New trial record